Epoch Investment Partners Inc. Cuts Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Epoch Investment Partners Inc. cut its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 7.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 58,264 shares of the medical research company's stock after selling 4,433 shares during the quarter. Epoch Investment Partners Inc.'s holdings in Amgen were worth $15,186,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Forum Financial Management LP lifted its holdings in shares of Amgen by 0.7% in the 4th quarter. Forum Financial Management LP now owns 352,784 shares of the medical research company's stock worth $91,950,000 after acquiring an additional 2,411 shares during the last quarter. Capital International Investors grew its holdings in Amgen by 40.1% during the fourth quarter. Capital International Investors now owns 12,212,065 shares of the medical research company's stock valued at $3,182,843,000 after purchasing an additional 3,495,503 shares during the period. Capital International Sarl boosted its stake in shares of Amgen by 183.4% in the fourth quarter. Capital International Sarl now owns 10,926 shares of the medical research company's stock worth $2,848,000 after acquiring an additional 7,071 shares during the period. Allred Capital Management LLC increased its holdings in shares of Amgen by 4.8% in the fourth quarter. Allred Capital Management LLC now owns 3,103 shares of the medical research company's stock worth $809,000 after purchasing an additional 143 shares during the last quarter. Finally, Fairfield Bush & CO. lifted its holdings in shares of Amgen by 12.4% in the 4th quarter. Fairfield Bush & CO. now owns 3,671 shares of the medical research company's stock valued at $957,000 after acquiring an additional 404 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company's stock.

Wall Street Analyst Weigh In

AMGN has been the topic of several analyst reports. Piper Sandler Companies reiterated an "overweight" rating and issued a $310.00 target price on shares of Amgen in a research note on Thursday, January 2nd. Bank of America raised their price objective on Amgen from $275.00 to $294.00 and gave the stock an "underperform" rating in a research report on Wednesday, March 5th. Truist Financial reduced their target price on shares of Amgen from $333.00 to $298.00 and set a "hold" rating on the stock in a report on Wednesday, January 8th. Cantor Fitzgerald began coverage on Amgen in a research report on Tuesday. They set a "neutral" rating and a $305.00 price objective for the company. Finally, Morgan Stanley upped their target price on shares of Amgen from $328.00 to $330.00 and gave the company an "equal weight" rating in a report on Wednesday, April 9th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Amgen currently has an average rating of "Hold" and an average target price of $310.57.

Amgen Stock Down 0.2 %

Shares of Amgen stock traded down $0.49 during trading hours on Wednesday, reaching $277.91. The company's stock had a trading volume of 2,679,236 shares, compared to its average volume of 2,789,034. The company has a market capitalization of $149.42 billion, a P/E ratio of 36.81, a P/E/G ratio of 2.63 and a beta of 0.59. The stock's fifty day simple moving average is $302.25 and its two-hundred day simple moving average is $293.45. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. On average, research analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be given a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 annualized dividend and a yield of 3.43%. Amgen's payout ratio is 126.09%.

Insider Activity

In other Amgen news, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the sale, the senior vice president now directly owns 7,210 shares of the company's stock, valued at $2,195,228.70. This trade represents a 18.06 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Jonathan P. Graham sold 25,045 shares of the company's stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the sale, the executive vice president now owns 28,987 shares in the company, valued at $8,496,669.44. This represents a 46.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 69,341 shares of company stock valued at $20,644,335. Insiders own 0.69% of the company's stock.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.